{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T23:37:57Z","timestamp":1794613077662,"version":"4.9.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1136\/ijgc-00009577-200511001-00015","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T14:42:23Z","timestamp":1717080143000},"page":"274-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":335,"special_numbering":"S3","title":["New tumor markers: CA125 and beyond"],"prefix":"10.1016","volume":"15","author":[{"suffix":"JR","given":"R.C.","family":"Bast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Badgwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.A.","family":"Baggerly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.N.","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Skates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lokshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0005","doi-asserted-by":"crossref","first-page":"27371","DOI":"10.1074\/jbc.M103554200","article-title":"Molecular cloning of the CA125 antigen: identification as a new mucin, MUC 16","volume":"276","author":"Yin","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0010","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1159\/000050638","article-title":"The CA125 gene: an extracellular superstructure dominated by repeat sequences","volume":"22","author":"O\u2019Brien","year":"2001","journal-title":"Tumour Biol"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0015","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1172\/JCI110380","article-title":"Reactivity of a monoclonal antibody with human ovarian carcinoma","volume":"681","author":"Bast","year":"1981","journal-title":"J Clin Invest"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0020","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJM198310133091503","article-title":"A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer","volume":"309","author":"Bast","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0025","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1158\/1078-0432.CCR-03-0787","article-title":"Recommendations for the use of CA 125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer","volume":"10","author":"Rustin","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0030","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/j.1471-0528.1993.tb15177.x","article-title":"Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3","volume":"100","author":"Jacobs","year":"1993","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0035","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1471-0528.1990.tb02448.x","article-title":"A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer","volume":"97","author":"Jacobs","year":"1990","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0040","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/0002-9378(90)90680-6","article-title":"The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction","volume":"163","author":"Hunter","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0045","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/humu.10181","article-title":"TP53 and ovarian cancer","volume":"21","author":"Schuijer","year":"2003","journal-title":"Hum Mutat"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0050","first-page":"1311","article-title":"Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines","volume":"63","author":"Selvakumaran","year":"2003","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2004.09.007","article-title":"Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs","volume":"53","author":"Safaei","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0060","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3727\/096504003108748410","article-title":"Cisplatin resistance in an ovarian cancer is associated with a defect in programmed cell death control through XIAP regulation","volume":"13","author":"Mansouri","year":"2003","journal-title":"Oncol Res"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0065","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III and IV ovarian cancer: a gynecologic oncology group study","volume":"18","author":"Muggia","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0070","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ygyno.2003.11.053","article-title":"Expression of multidrug resistance protein-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples","volume":"93","author":"Penson","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0075","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1038\/sj.onc.1206934","article-title":"Mechanisms of taxol resistance related to microtubules","volume":"22","author":"Orr","year":"2003","journal-title":"Oncogene"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0080","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0093-7754(01)90277-5","article-title":"Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers","volume":"28","author":"Yu","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0085","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1007\/s00018-002-8518-3","article-title":"Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer","volume":"59","author":"Zaffaroni","year":"2002","journal-title":"Cell Mol Life Sci"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0090","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1006\/gyno.2002.6797","article-title":"Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients","volume":"87","author":"Holloway","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0095","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1158\/1078-0432.CCR-04-1673","article-title":"Gene expression profiles predict early relapse in ovarian cancer following platinum-paclitaxel chemotherapy","volume":"11","author":"Hartmann","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0100","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1136\/bmj.306.6884.1025","article-title":"Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging","volume":"306","author":"Bourne","year":"1993","journal-title":"Br Med J"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0105","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1006\/gyno.2000.5816","article-title":"The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer","volume":"77","author":"Van Nagell","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0110","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/1097-0142(20000801)89:3<582::AID-CNCR13>3.0.CO;2-#","article-title":"Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography","volume":"89","author":"Sato","year":"2001","journal-title":"Cancer"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0115","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0090-8258(85)90015-0","article-title":"Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma","volume":"22","author":"Bast","year":"1985","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0120","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ijc.2910420507","article-title":"Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer","volume":"42","author":"Zurawski","year":"1988","journal-title":"Int J Cancer"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0125","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-1-4757-3587-1_3","article-title":"Early detection of ovarian cancer: promise and reality","volume":"107","author":"Bast","year":"2002","journal-title":"Cancer Treat Res"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0130","first-page":"268","article-title":"Multimodal approach to screening for ovarian cancer","volume":"1","author":"Jacobs","year":"1999","journal-title":"Lancet"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0135","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/1097-0142(19951115)76:10+<2004::AID-CNCR2820761317>3.0.CO;2-G","article-title":"Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers","volume":"76","author":"Skates","year":"1995","journal-title":"Cancer"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0140","first-page":"1957","article-title":"New monoclonal antibodies identify the glycoprotein carrying the CA125 eptitope","volume":"165","author":"O\u2019Brien","year":"1991","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0145","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1200\/JCO.2003.02.955","article-title":"Calculation of the risk of ovarian cancer from serial CA-125 values for pre-clinical detection in postmenopausal women","volume":"21","author":"Skates","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0150","unstructured":"Menon U, Skates S, Lewis S et al. A prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol. In press."},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0155","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1074\/mcp.R400006-MCP200","article-title":"Progress and challenges in screening for early detection of ovarian cancer","volume":"3","author":"Jacobs","year":"2004","journal-title":"Mol Cell Proteomics"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0160","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1158\/1078-0432.CCR-03-0409","article-title":"Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis","volume":"10","author":"Lu","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0165","doi-asserted-by":"crossref","first-page":"11531","DOI":"10.1073\/pnas.96.20.11531","article-title":"Soluble member(s) of the mesothelin\/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma","volume":"96","author":"Scholler","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0170","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0002-9378(12)90761-9","article-title":"Increased serum levels of macrophage colony-stimulating factor in ovarian cancer","volume":"165","author":"Xu","year":"1991","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0175","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jama.280.8.719","article-title":"Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers","volume":"280","author":"Xu","year":"1998","journal-title":"JAMA"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0180","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0378-1119(99)00342-X","article-title":"Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas","volume":"238","author":"Schummer","year":"1999","journal-title":"Gene"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0185","first-page":"579","article-title":"Human kallikrein 6 (zyme\/protease M\/neurosin): a new serum biomarker of ovarian carcinoma","volume":"33","author":"Diamandis","year":"2000","journal-title":"Clin Bio- chem"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0190","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0009-8981(01)00401-6","article-title":"Human kallikrein 10: a novel tumor marker for ovarian carcinoma?","volume":"306","author":"Luo","year":"2001","journal-title":"Clin Chim Acta"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0195","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/93.19.1458","article-title":"Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology","volume":"93","author":"Mok","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0200","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1001\/jama.287.13.1671","article-title":"Osteopontin as a potential diagnostic for ovarian cancer","volume":"287","author":"Kim","year":"2002","journal-title":"JAMA"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0205","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2004.07.039","article-title":"Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma","volume":"95","author":"McIntosh","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0210","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian cancer","volume":"63","author":"Hellstrom","year":"2003","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0215","unstructured":"Rosen D, Wang L, Atkinson JN et al. Potential markers that complement expression of CA 125 in epithelial ovarian cancer. Gynecol Oncol. In press."},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0220","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(02)07746-2","article-title":"Use of pro- teomic patterns in serum to identify ovarian cancers","volume":"359","author":"Petricoin","year":"2002","journal-title":"Lancet"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0225","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/jnci\/dji008","article-title":"Signal in noise: evaluating reported reproducibility of proteomic tests for ovarian cancer","volume":"97","author":"Baggerly","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0230","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.1158\/0008-5472.CAN-04-0746","article-title":"A panel of serum biomarkers identified through proteomic profiling for the detection of early stage ovarian cancer","volume":"64","author":"Zhang","year":"2004","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0235","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0022-1759(00)00238-6","article-title":"Multiplexed particle-based flow cytometric assays","volume":"243","author":"Vignali","year":"2000","journal-title":"J Immunol Methods"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0240","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1158\/1055-9965.EPI-04-0404","article-title":"Multiplexed immunobead\u2013based cytokine profiling for early detection of ovarian cancer","volume":"14","author":"Gorelik","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0245","unstructured":"Zhang Z, Xu F-J, Yu Y et al. Detection of stage I epithelial ovarian cancer using an artificial neural network derived composite index of multiple serum markers. Submitted for publication."},{"key":"10.1136\/ijgc-00009577-200511001-00015_bb0250","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1200\/JCO.2004.03.091","article-title":"Pre-operative sensitivity and specificity for early stage ovarian cancer when combining CA 125, CA 15.3, CA 72.4 and M-CSF using mixtures of multivariate normal distributions","volume":"22","author":"Skates","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24193176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24193176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-00009577-200511001-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T12:33:46Z","timestamp":1753101226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24193176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":50,"aliases":["10.1111\/j.1525-1438.2005.00441.x"],"alternative-id":["S1048891X24193176"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-00009577-200511001-00015","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New tumor markers: CA125 and beyond","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-00009577-200511001-00015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 IGCS","name":"copyright","label":"Copyright"}]}}